论文部分内容阅读
目的探讨常规治疗基础上加用黄芪注射液治疗小儿病毒性心肌炎(VMC)的疗效。方法随机将64例VMC患儿分为对照组和观察组各32例,对照组给予常规治疗,观察组在对照组基础上加用黄芪注射液,观察两组治疗后临床疗效、心电图、心肌酶变化及药物不良反应情况。结果两组总有效率分别为90.63%和65.63%,观察组明显优于对照组(P<0.05),且心电图改善也显著优于对照组(P<0.05);观察组心肌酶改善程度较对照组显著(P<0.05)。两组治疗期间均未发生明显不良反应。结论在常规治疗基础上加用黄芪注射液治疗小儿病毒性心肌炎疗效显著,患儿不良反应少,值得基层医院推广应用。
Objective To investigate the curative effect of adding Astragalus injection on children with viral myocarditis (VMC) based on routine treatment. Methods Sixty-four patients with VMC were randomly divided into two groups: control group and observation group, with 32 cases in each group. The control group was given routine treatment. The observation group was given astragalus injection on the basis of the control group. The clinical effects, electrocardiogram, Changes and adverse drug reactions. Results The total effective rates of the two groups were 90.63% and 65.63% respectively. The observation group was significantly better than the control group (P <0.05), and the improvement of electrocardiogram was also significantly better than that of the control group (P <0.05) Group was significant (P <0.05). No significant adverse reactions occurred during the two groups. Conclusion The addition of Astragalus injection on the basis of routine treatment has obvious curative effect on viral myocarditis in children and little adverse reaction in children, which is worth popularizing and applying in primary hospitals.